The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month. Novo Nordisk's Wegovy Gets EU Backing to Treat ...

Collaboration between giant pharmaceutical corporations and patients with very little power just doesn’t work, according to ...

Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?